BAKER BROS ADVISORS LP
Q4 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001263508
· CRD 158149
· SEC-registered investment adviser
$16.7B Reported Value Total
BAKER BROTHERS INVESTMENTS reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $23,154,517,129, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
7 funds
· $28.2B gross asset value
Hedge Fund: $28.2B
Source: Form ADV filed 2026-03-27
Reported value
$16.7B
Quarter over quarter
+11.4%
Holdings
111
Top-10 concentration
87.0%
Key People
Form ADV owners & control persons
Felix James Baker
MANAGING MEMBER
Julian Charles Baker
MANAGING MEMBER
Scott Lawrence Lessing
PRESIDENT, CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $16.7B |
| Positions | 111 |
| Change in reported value | +9.1% |
| New positions | 14 |
| Exited positions | 16 |
| Position turnover | 23.6% |
| Top-10 concentration | 87.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
83 | $20.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
84 | $17.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
85 | $17.1B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
89 | $13.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
88 | $10.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
87 | $9.0B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
93 | $9.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
92 | $9.6B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
93 | $7.8B |
|
Q1 2024 13F
Filed May 15, 2024
|
87 | $8.0B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
82 | $8.8B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
99 | $17.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
106 | $17.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
105 | $18.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
111 | $16.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
113 | $15.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
114 | $17.6B |
|
Q1 2022 13F
Filed May 16, 2022
|
115 | $17.4B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
116 | $20.6B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
116 | $22.8B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SGEN Seagen Inc. | $6.0B | 36.21% |
| 2 | INCY Incyte Corporation | $2.9B | 17.44% |
| 3 | ONC BeiGene, Ltd. | $2.6B | 15.41% |
| 4 | BMRN BioMarin Pharmaceutical Inc. | $788.6M | 4.74% |
| 5 | ACAD ACADIA Pharmaceuticals Inc. | $667.4M | 4.01% |
| 6 | ASND Ascendis Pharma A/S | $605.1M | 3.63% |
| 7 | MDGL Madrigal Pharmaceuticals, Inc. | $448.5M | 2.69% |
| 8 | RYTM Rhythm Pharmaceuticals, Inc. | $185.0M | 1.11% |
| 9 | BCRX BioCryst Pharmaceuticals, Inc. | $145.9M | 0.88% |
| 10 | IMCR Immunocore Holdings plc | $143.9M | 0.86% |
| 11 | AKRO Akero Therapeutics, Inc. | $129.8M | 0.78% |
| 12 | REPL Replimune Group, Inc. | $124.5M | 0.75% |
| 13 | KOD Kodiak Sciences Inc. | $123.9M | 0.74% |
| 14 | HZNP Horizon Therapeutics Public Ltd Co | $110.4M | 0.66% |
| 15 | ARGX argenx SE | $106.1M | 0.64% |
| 16 | ABCL AbCellera Biologics Inc. | $105.9M | 0.64% |
| 17 | KYMR Kymera Therapeutics, Inc. | $71.9M | 0.43% |
| 18 | KDNY Chinook Therapeutics, Inc. | $66.4M | 0.4% |
| 19 | TRDA Entrada Therapeutics, Inc. | $65.8M | 0.4% |
| 20 | MRTX Mirati Therapeutics, Inc. | $63.9M | 0.38% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.